Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

被引:46
作者
Chen, Xuxing [1 ,2 ]
Huan, Xiajuan [3 ]
Liu, Qiufeng [2 ,4 ]
Wang, Yuqin [1 ]
He, Qian [1 ]
Tan, Cun [1 ]
Chen, Yi [3 ]
Ding, Jian [3 ]
Xu, Yechun [4 ]
Miao, Zehong [3 ]
Yang, Chunhao [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Synthet Organ & Med Chem Lab, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[2] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[4] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
PARP1/2; inhibitor; Benzimidazole; 4,5,6,7-Tetrahydrothienopyridine; Co-crystal structure; Isothermal Titration Calorimetry; CANCER-THERAPY; POLYMERASE INHIBITORS; BIOLOGICAL EVALUATION; ANTICANCER ACTIVITY; EXCISION-REPAIR; CELLS; TARGETS; CYTOTOXICITY; ACTIVATION; BINDING;
D O I
10.1016/j.ejmech.2018.01.018
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The nuclear protein poly(ADP-ribose) polymerases-1/2 (PARP-1/2) are involved in DNA repair damaged by endogenous or exogenous process. And PARP-1/2 inhibitors have been proved to be clinically efficacious for DNA repair deficient tumors in the past decade. We have developed a series of 4,5,6,7-tetrahydrothienopyridin-2-yl benzimidazole carboxamides as novel and potent PARP-1/2 inhibitors. The best compound resulted from this series is compound 27 which displays excellent PARP-1 and PARP-2 inhibitory activity with IC50 of 18 nM and 42 nM, respectively. Furthermore, it can selectively kill BRCA2 deficient V-C8 cells with a CC50 of 920 nM. In the MDA-MB-436 (BRCA-1 mutant) xenograft model, this compound was well tolerated and showed single-agent activity. Based on the results above, compound 27 has been selected as a lead candidate targeting PARP-1/2 and its preclinical characterization is also underway. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:389 / 403
页数:15
相关论文
共 39 条
[31]   DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite [J].
Szabo, C ;
Zingarelli, B ;
OConnor, M ;
Salzman, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1753-1758
[32]   New PARP targets for cancer therapy [J].
Vyas, Sejal ;
Chang, Paul .
NATURE REVIEWS CANCER, 2014, 14 (07) :502-509
[33]   Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent [J].
Wang, Bing ;
Chu, Daniel ;
Feng, Ying ;
Shen, Yuqiao ;
Aoyagi-Scharber, Mika ;
Post, Leonard E. .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (01) :335-357
[34]   An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy [J].
Wang, Ying-Qing ;
Wang, Ping-Yuan ;
Wang, Yu-Ting ;
Yang, Guang-Fu ;
Zhang, Ao ;
Miao, Ze-Hong .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (21) :9575-9598
[35]   MICE LACKING ADPRT AND POLY(ADP-RIBOSYL)ATION DEVELOP NORMALLY BUT ARE SUSCEPTIBLE TO SKIN-DISEASE [J].
WANG, ZQ ;
AUER, B ;
STINGL, L ;
BERGHAMMER, H ;
HAIDACHER, D ;
SCHWEIGER, M ;
WAGNER, EF .
GENES & DEVELOPMENT, 1995, 9 (05) :509-520
[36]   Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors [J].
Ye, Na ;
Chen, Chuan-Huizi ;
Chen, TianTian ;
Song, Zilan ;
He, Jin-Xue ;
Huan, Xia-Juan ;
Song, Shan-Shan ;
Liu, Qiufeng ;
Chen, Yi ;
Ding, Jian ;
Xu, Yechun ;
Miao, Ze-Hong ;
Zhang, Ao .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) :2885-2903
[37]   PARP-10, a novel Myc-interacting protein with poly( ADP-ribose) polymerase activity, inhibits transformation [J].
Yu, M ;
Schreek, S ;
Cerni, C ;
Schamberger, C ;
Lesniewicz, K ;
Poreba, E ;
Vervoorts, J ;
Walsemann, G ;
Grötzinger, J ;
Kremmer, E ;
Mehraein, Y ;
Mertsching, J ;
Kraft, R ;
Austen, M ;
Lüscher-Firzlaff, J ;
Lüscher, B .
ONCOGENE, 2005, 24 (12) :1982-1993
[38]   Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials [J].
Yuan, Bo ;
Ye, Na ;
Song, Shan-Shan ;
Wang, Yu-Ting ;
Song, Zilan ;
Chen, Hua-Dong ;
Chen, Chuan-Huizi ;
Huan, Xia-Juan ;
Wang, Ying-Qing ;
Su, Yi ;
Shen, Yan-Yan ;
Sun, Yi-Ming ;
Yang, Xin-Ying ;
Chen, Yi ;
Guo, Shi-Yan ;
Gan, Yong ;
Gao, Zhi-Wei ;
Chen, Xiao-Yan ;
Ding, Jian ;
He, Jin-Xue ;
Zhang, Ao ;
Miao, Ze-Hong .
CANCER LETTERS, 2017, 386 :47-56
[39]   PARP inhibitor development for systemic cancer targeting [J].
Zaremba, Tomasz ;
Jane-Curtin, Nicola .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (05) :515-523